KOSDAQHotel & Leisure072990

HCT

₩2,890 0.00%2026-11-18 close
Market Cap
₩41.9B
Turnover
₩24,208,185
Volume
8.6K
Shares out.
14.5M
PER
—
PBR
0.4×
EPS
-₩70
Dividend Yield
1.56%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩45 per share · Prices as of the 2026-11-18 close

01

Report overview

Testing Business Back in the Black; Repeat Losses Still the Question

HCT's testing and certification business returned to operating profit in the third quarter of 2026, but operating losses in the fourth quarter of 2025 and the second quarter of 2026 mean earnings recovery is still unconfirmed.

  1. 1

    Operating profit in the third quarter of 2026 was KRW 2.52 billion, a swing back to profit from an operating loss of KRW 403 million in the second quarter. Revenue of KRW 27.6 billion rose 7.6% from the prior quarter but fell 1.8% from a year earlier.

  2. 2

    Annual revenue rose for three consecutive years from 2023 through 2025, reaching KRW 107.5 billion in 2025. Operating profit peaked at KRW 11.2 billion in 2024 and fell to KRW 8.27 billion in 2025, while the operating margin dropped from 11.9% to 7.7%.

  3. 3

    Cumulative January to September 2026 preliminary results, announced on November 9, 2026 and not yet audited, show revenue of KRW 77.9 billion (down 6.1% year on year) and operating profit of KRW 2.52 billion (down 76.8%).

  4. 4

    Overseas and bio operations are cited as secondary drivers. The U.S. subsidiary posted profits in both the second and third quarters of 2026 after its facility expansion, and the bio subsidiary H&H Bio reported third-quarter 2026 revenue of KRW 2.2 billion, up 315.2% year on year.

  5. 5

    In August 2026 Kwon Yong-taek was appointed co-CEO, and management placed profitability recovery and restructuring of the business at the center of its agenda.

02

Business structure

HCT is a testing, certification and calibration company that verifies product safety, quality and compliance with environmental regulations for electrical and electronic products.

As of a June 2025 company profile tally, services accounted for 98.16% of revenue and goods for 1.84%, so most revenue comes from testing and certification work.

The core information and communications technology (ICT) testing unit's orders and sales move with demand for electromagnetic compatibility (EMC) and other certifications for new products. In the third quarter of 2026 the company said ICT testing orders recovered, lifting sales and profit from the prior quarter.

Overseas, the U.S. subsidiary recorded a profit in both the second and third quarters of 2026 after completing test chamber and facility expansion.

The bio subsidiary H&H Bio, a newer business, reported third-quarter 2026 revenue of KRW 2.2 billion, up 315.2% year on year, though it remains small relative to group revenue of KRW 27.6 billion. The company said its M Solution Center has begun full operation.

Competition comes from many domestic private testing bodies, and operating capacity and certification track record underpin order wins. In August 2026 Kwon Yong-taek was appointed co-CEO alongside Heo Bong-jae.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩28.1B₩4.5B15.9%
2025Q4₩24.6B-₩2.6B−10.5%
2026Q1₩24.7B₩400M1.6%
2026Q2₩25.6B-₩400M−1.6%
2026Q3₩27.6B₩2.5B9.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩67.1B₩6.5B₩5.8B9.6%7.9%73.9%
2023₩74.1B₩8B₩7.4B10.8%9.1%68.5%
2024₩94.4B₩11.2B₩7B11.9%7.6%77.1%
2025₩107.5B₩8.3B₩6.3B7.7%6.6%87.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue was KRW 67.1 billion in 2022, KRW 74.1 billion in 2023 (up 10.4%), KRW 94.4 billion in 2024 (up 27.4%) and KRW 107.5 billion in 2025 (up 13.9%), rising for three consecutive years from 2023 through 2025, with 2025 the largest year in the 2022 to 2025 period.

Operating profit grew from KRW 6.46 billion in 2022 to KRW 8.01 billion in 2023 (up 24.1%) and KRW 11.2 billion in 2024 (up 39.9%), then fell to KRW 8.27 billion in 2025 (down 26.2%).

The operating margin rose from 9.6% in 2022 to 10.8% in 2023 and 11.9% in 2024, then dropped to 7.7% in 2025, so revenue growth did not carry through to profitability.

Profit attributable to controlling shareholders peaked at KRW 7.37 billion in 2023 (up 27.2%) and then declined for two consecutive years, to KRW 7.01 billion in 2024 (down 4.9%) and KRW 6.29 billion in 2025 (down 10.2%). Net income including non-controlling interests, a separate measure, was KRW 5.22 billion in 2025.

On a quarterly basis, operating profit of KRW 4.45 billion in the third quarter of 2025 turned into an operating loss of KRW 2.59 billion in the fourth quarter of 2025.

The first quarter of 2026 returned to a small operating profit of KRW 405 million, the second quarter swung back to an operating loss of KRW 403 million, which the company linked to adjustments in ICT testing volume, and the third quarter recorded operating profit of KRW 2.52 billion, down 43.4% from a year earlier.

Preliminary cumulative results for January to September 2026, announced on November 9, 2026, show operating profit of KRW 2.52 billion, down 76.8% year on year.

Profit attributable to controlling shareholders for the third quarter of 2026 was KRW 1.57 billion, down 55.0% year on year, and the sum over the latest four quarters is a loss of KRW 1.05 billion.

The debt ratio rose to 87.6% at the end of 2025 from 73.9% in 2022, while operating cash flow increased from KRW 16.3 billion in 2022 to KRW 34.6 billion in 2025, so cash generation improved even as margins compressed.

05

Industry analysis

Testing and certification demand is tied to product launch cycles in electronics, batteries and communications equipment. Orders tend to rise when new products launch in volume and fall when launches are delayed.

HCT's core ICT testing unit saw orders recover in the third quarter of 2026, according to the company, which shows that shifts in downstream electronics demand feed directly into results.

Testing is equipment- and labor-intensive, so utilization largely determines margins; the fall in the operating margin to 7.7% in 2025 and the second-quarter 2026 loss tied to volume adjustments illustrate this structure.

Competition spans large public testing bodies, domestic private labs and foreign certification bodies. HCT's positioning rests on covering several fields in one place, including electromagnetic compatibility (EMC), wireless certification and battery safety testing.

Overseas, the U.S. subsidiary serves local certification demand, and its profits in the second and third quarters of 2026 suggest higher utilization at the overseas base. Local demand, exchange rates and changes in certification standards are external variables whose effect must be tracked in quarterly disclosures.

The bio business is still small relative to group revenue, so the order flow in the core testing business continues to drive results.

06

Outlook

The company said it intends to keep its earnings improvement trend going into the fourth quarter of 2026. When it reported second-quarter 2026 results, it expressed expectations that profitability would improve in the second half.

The stated basis for that view was recovery in ICT testing orders, continued quarterly profits at the U.S. subsidiary and the operation of the M Solution Center.

Under the co-CEO structure set up in August 2026, management has pledged cost efficiency and stronger core business competitiveness, and said restoring profitability and customer trust is the most important task.

Confirmed facts are the return to operating profit in the third quarter of 2026 and two consecutive quarters of profit at the U.S. subsidiary. However, cumulative operating profit for January to September 2026 is down 76.8% year on year, so how much of the annual decline the second half can reverse remains open.

The next checkpoints are whether fourth-quarter 2026 results extend the third-quarter profit and whether ICT order recovery translates into higher revenue. Whether the bio subsidiary's growth lifts its revenue contribution is also worth tracking.

Specific figures for cost efficiency and restructuring have not yet been presented, and more detail is expected in the annual report and investor relations materials.

07

Valuation

PER
—
PBR
0.4×
ROE
-1.1%
EPS
-₩70
BPS
₩6,652
Dividend per share
₩45

Because the sum of profit attributable to controlling shareholders over the latest four quarters is a loss of KRW 1.05 billion, earnings-based multiples cannot be calculated at present. A price-to-earnings comparison depends on how many quarters the return to profit lasts.

On an asset basis, the price-to-book ratio places the stock in the lower range relative to net assets. Total equity at the end of 2025 was KRW 96.8 billion, of which KRW 95.6 billion was attributable to controlling shareholders, and the gap between asset value and share price should be read against this capital base.

However, a low price relative to book value can persist if asset quality and profitability do not support it, so PBR alone is hard to interpret. The debt ratio rose to 87.6% in 2025 from 73.9% in 2022, which should be read alongside asset-based comparisons as a financial burden.

Dividends can vary with earnings, so the dividend level is best checked together with the durability of the profit recovery. On a multi-year basis, the starting point for valuation interpretation is that profit attributable to controlling shareholders peaked in 2023 and then declined for two consecutive years.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

ICT order recovery and consecutive revenue growth

Revenue has risen for three consecutive quarters since the fourth-quarter 2025 low, running from the first quarter through the third quarter of 2026. The company said ICT testing orders recovered in the third quarter of 2026. The link between that sales recovery and the return to operating profit is the core basis for this view.

Growth at the overseas and bio subsidiaries

The U.S. subsidiary posted profits in both the second and third quarters of 2026 after its facility expansion. Bio subsidiary H&H Bio reported third-quarter 2026 revenue of KRW 2.2 billion, up 315.2% year on year.

If these two units become established sources of income beyond the core business, the diversification effect could grow.

Capital base and improving operating cash flow

Total equity at the end of 2025 was KRW 96.8 billion, with KRW 95.6 billion attributable to controlling shareholders. Operating cash flow rose from KRW 16.3 billion in 2022 to KRW 34.6 billion in 2025. Improved cash generation during a period of lower profit is a positive factor for financial stability.

09

Bear factors

Sharp decline in cumulative 2026 results

Preliminary cumulative revenue for January to September 2026 fell 6.1% year on year, and cumulative operating profit fell 76.8%. These figures were announced as preliminary results on November 9, 2026. Despite the third-quarter return to profit, weak earlier quarters pulled cumulative results sharply lower.

Erosion of profitability and loss-making quarters

The operating margin fell from 11.9% in 2024 to 7.7% in 2025. Operating losses were recorded in the fourth quarter of 2025 and the second quarter of 2026, and the sum of profit attributable to controlling shareholders over the latest four quarters is a loss of KRW 1.05 billion. Revenue growth that does not reach profit is a recurring weakness.

Rising financial leverage

The debt ratio rose from 73.9% in 2022 and 68.5% in 2023 to 77.1% in 2024 and 87.6% in 2025, increasing in each of the last two years. Total liabilities at the end of 2025 were KRW 84.8 billion. When profit stalls or falls while debt rises, the financial burden becomes more sensitive to earnings swings.

10

Risk factors

Order volatility

ICT testing orders change with downstream electronics launch schedules and volumes. Press reports tied the second-quarter 2026 operating loss mainly to adjustments in ICT testing volume. If the recovery lasts only a quarter or two, results could swing again.

Balance sheet pressure

At the end of 2025 total liabilities were KRW 84.8 billion against total equity of KRW 96.8 billion, with the debt ratio at 87.6%. If borrowing costs rise during a period of falling profit, room for facility investment and operations could shrink. Whether operating cash flow keeps improving is the benchmark for gauging this risk.

Execution of restructuring

The co-CEO structure launched in August 2026 set cost efficiency and business restructuring as priorities. Specific plans and their effects have not yet been presented in figures. Cost or workforce adjustments during restructuring could weigh on short-term results.

11

What to watch next

  1. Early 2027 (date not yet set)

    Fourth-quarter and full-year 2026 preliminary results. The checkpoints are whether the third-quarter profit carries into the fourth quarter and where the annual operating margin lands from 7.7% in 2025.

  2. End of March 2027

    Filing of the 2026 annual report. Confirmed annual revenue, operating profit, debt ratio and operating cash flow will be updated as official disclosed figures. This is the point to check any differences between preliminary and audited numbers.

  3. Around the March 2027 annual general meeting (date not yet set)

    Dividend decisions and confirmation of the management structure. Details of the cost-efficiency plan put forward under the co-CEO setup could be disclosed around this time.

  4. First-quarter 2027 results release (date not yet set)

    A checkpoint to see whether the U.S. subsidiary's profits continue and whether ICT order recovery translates into higher revenue. The growth of bio subsidiary sales is also worth tracking.

12

Overall view

HCT is a company focused on testing, certification and calibration. Revenue rose for three consecutive years from 2022 through 2025 to KRW 107.5 billion in 2025. Operating profit, however, peaked at KRW 11.2 billion in 2024 and fell to KRW 8.27 billion in 2025, with the operating margin dropping to 7.7%.

In the third quarter of 2026 operating profit returned to KRW 2.52 billion, supported by recovering ICT testing orders and continued profit at the U.S. subsidiary.

Preliminary cumulative operating profit for January to September 2026, announced on November 9, 2026, was down 76.8% year on year, so the weak early-2026 quarters still weigh on the year.

Profit attributable to controlling shareholders over the latest four quarters is a loss of KRW 1.05 billion, and the debt ratio rose to 87.6% in 2025. On the strength side, revenue recovery, overseas profits, bio subsidiary growth and improving operating cash flow are visible.

On the weakness side, cumulative declines, recurring loss-making quarters and higher financial leverage stand out. The next checkpoints are the preliminary fourth-quarter 2026 results and the 2026 annual report, and how many quarters the return to profit lasts will be central to judging earnings strength.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. calculator.io.kr
  3. newspim.com
  4. en.edaily.co.kr
  5. comp.wisereport.co.kr
  6. news.nate.com
  7. wowtv.co.kr
  8. kind.krx.co.kr
  9. news.nate.com
  10. vegannews.co.kr
  11. digitaltoday.co.kr
  12. thedailypost.kr
  13. specialtimes.co.kr
  14. msn.com
  15. edaily.co.kr
  16. vegannews.co.kr
  17. edaily.co.kr
  18. edaily.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis